ORA and CDER agree to replace and/or withdraw CPGs in favor of using guidance or procedural documents, as appropriate per GGP regulations.
Similar Posts
Extended-Release Stimulants for ADHD: FDA Drug Safety Communication – FDA Requires Expanded Labeling about Weight Loss Risk in Patients Younger than 6 Years
The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo“Peter Michael, M.D. – 711299 – 06/18/2025
Clinical InvestigatorFDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
FDA is warning that getting alcohol-based hand sanitizer in the eyes can cause serious injury. If this occurs, immediately rinse with running water for 15 to 20 minutesFDA Drug Competition Action Plan
FDA’s Drug Competition Action Plan (DCAP) encourages robust and timely market competition for generic drugs and helps bring greater efficiency and transparency to the generic drug review process, without sacrificing the scientific rigor underlying our generic drug program.Green Lumber Holding, LLC Issues Consumer Alert on Counterfeit Products Following FDA Findings
Costa Mesa, California August 28, 2025 – Green Lumber Holding, LLC (“Green Lumber”) is alerting consumers that counterfeit products misrepresented as genuine Green Lumber have been identified and may pose health risks.Recall Alert: BALT USA Removes MEGA Ballast Distal Access Platform
Balt USA is removing their Mega Ballast because of the unintended presence of loose hydrophilic coating inside the tube at the tip end